Results 71 to 80 of about 136,011 (340)
New England Journal of Medicine, 2003 BACKGROUND Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial ...
J. Yang +8 more
semanticscholar +1 more source
Mass spectrometry in ocular drug research
Mass Spectrometry Reviews, EarlyView., 2023 Abstract Mass spectrometry (MS) has been proven as an excellent tool in ocular drug research allowing analyzes from small samples and low concentrations. This review begins with a short introduction to eye physiology and ocular pharmacokinetics and the relevance of advancing ophthalmic treatments.
Eva M. del Amo +6 more
wiley +1 more source
Frontiers in Immunology, 2020 Highly sensitive reporter-gene assays have been developed that allow both the direct vascular endothelial growth factor (VEGF) neutralizing activity of bevacizumab and the ability of bevacizumab to activate antibody dependent cellular cytotoxicity (ADCC)
Christophe Lallemand +8 more
doaj +1 more source
International Journal of Nephrology, 2021 Molecular mechanisms underlying the nephrotoxicity associated with bevacizumab are unclear. Endothelin-1 (ET-1) is involved in podocyte injury and proteinuria, and its level increases in most cases of kidney disorders.
Satoru Nihei +3 more
doaj +1 more source
Bowel Perforation in the Emergency Department Related to Bevacizumab Therapy and Recurrent Ovarian Cancer [PDF]
, 2020 Case Presentation: We describe the presentation to the emergency department of a patient with recurrent ovarian cancer treated with bevacizumab with the complication of bowel perforation.
Burleson, Samuel L. +3 more
core
Metformin: a modulator of bevacizumab activity in cancer? A case report. [PDF]
, 2015 Recurrent type I endometrial cancer ((EC)) has poor prognosis and demands novel therapeutic approaches. Bevacizumab, a VEGF-A neutralizing monoclonal antibody, has shown clinical activity in this setting. To our knowledge, however, although some diabetic
Aliberti, C +7 more
core +1 more source
Therapeutics and Clinical Risk Management, 2015 Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves cerebral edema, and is expected to improve neurologic ...
openaire +5 more sources
Mammakarzinom: Bevacizumab nach Progression unter Bevacizumab? [PDF]
gynäkologie + geburtshilfe, 2017 Der Antikorper Bevacizumab hemmt mit dem VEGF („vascular endothelial growth factor“) ein Schlusselmolekul fur die Vaskularisierung von Tumorzellen. Profitieren Brustkrebspatientinnen mit einem Rezidiv nach der First-Line-Therapie mit Bevacizumab von dem VEGF-Antikorper in der Zweitlinie?
openaire +3 more sources
Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer. [PDF]
, 2018 Posterior reversible encephalopathy syndrome (PRES) is an increasingly recognizable neuro-clinical syndrome. Clinical and neurological manifestations of PRES include hypertension, headache, encephalopathy, seizures, and symmetrical white matter changes ...
Ghani, Ali +5 more
core +2 more sources
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Journal of Clinical Oncology, 2009 PURPOSE We evaluated the efficacy of bevacizumab, alone and in combination with irinotecan, in patients with recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial. PATIENTS AND METHODS One hundred sixty-seven patients were
H. Friedman +13 more
semanticscholar +1 more source